Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Rating of “Hold” by Analysts

Pediatrix Medical Group, Inc. (NYSE:MD) has earned a consensus rating of “Hold” from the nine research firms that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $16.9286.

MD has been the subject of several recent analyst reports. Zacks Research cut Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Truist Financial set a $17.00 price objective on Pediatrix Medical Group in a research note on Tuesday, October 14th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Pediatrix Medical Group in a research note on Wednesday, October 8th. UBS Group raised their price objective on Pediatrix Medical Group from $16.00 to $16.50 and gave the company a “neutral” rating in a research note on Thursday, August 14th. Finally, Leerink Partners raised their price objective on Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a research note on Friday, September 5th.

Pediatrix Medical Group Stock Down 0.8%

MD opened at $17.45 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.80 and a quick ratio of 1.80. The business has a 50 day simple moving average of $16.76 and a 200-day simple moving average of $14.71. The stock has a market capitalization of $1.52 billion, a P/E ratio of 13.53 and a beta of 1.26. Pediatrix Medical Group has a 12 month low of $11.84 and a 12 month high of $18.22.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.42 by $0.11. The business had revenue of $468.84 million during the quarter, compared to analysts’ expectations of $464.37 million. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The company’s quarterly revenue was down 7.1% compared to the same quarter last year. During the same period last year, the firm earned $0.34 EPS. On average, equities analysts anticipate that Pediatrix Medical Group will post 1.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pediatrix Medical Group

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Pediatrix Medical Group by 219.5% in the 1st quarter. GAMMA Investing LLC now owns 2,569 shares of the company’s stock valued at $37,000 after purchasing an additional 1,765 shares in the last quarter. Marshall & Sullivan Inc. WA purchased a new position in Pediatrix Medical Group in the 2nd quarter valued at approximately $41,000. Canada Pension Plan Investment Board acquired a new stake in Pediatrix Medical Group during the 2nd quarter valued at $83,000. AlphaQuest LLC grew its holdings in Pediatrix Medical Group by 16.0% during the 1st quarter. AlphaQuest LLC now owns 5,877 shares of the company’s stock valued at $85,000 after buying an additional 811 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Pediatrix Medical Group during the 2nd quarter valued at $99,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.